FDA
-
-
-
-
-
-
-
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office
-
-
-
-
-
-
-
Citi Starts Amylyx Pharmaceuticals inc. (AMLX) at Buy
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
-
-
-
-
-
-
-
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

